The Piedmont Lithium Ltd (ASX: PLL) share price is among the worst performers on the All Ordinaries index on Thursday morning.

In early trade the lithium developer’s shares were down as much as 17% to 90.5 cents.

However, despite this decline, the Piedmont Lithium share price is still up a massive 145% since the start of the year.

Why is the Piedmont Lithium share price crashing lower?

Today’s decline appears to be a delayed response to the completion of its US$122.5 million capital raising earlier this week.

Overnight on Wall Street, Piedmont Lithium’s Nasdaq-listed shares fell a sizeable 16.4%.

Capital raising

Piedmont Lithium raised the US$122.5 million at an issue price of US$70.00 per American Depositary Share (ADS), which equates to 90.9 Australian cents per ASX-listed share.

The latter was a 15% discount to the Piedmont Lithium share price before its trading halt.

After costs, the company expects to receive proceeds of approximately US$114.5 million.

What are the funds for?

Piedmont Lithium intends to use the net proceeds from the offering to continue the development of the Piedmont Lithium Project in North America.

This includes definitive feasibility studies, testwork, permitting, further exploration drilling, mineral resource estimate updates, and ongoing land consolidation.

In addition to this, some of the proceeds will be used to fund its investment in fellow lithium developer Sayona Mining Ltd (ASX: SYA) and other possible strategic initiatives.

In respect to its Sayona Mining investment, the company intends to acquire up to 19.9% of Sayona Mining and 25% of Sayona Quebec.

After which, the Sayona Quebec business will ultimately supply Piedmont Lithium with the greater of 60,000 tonnes per annum or 50% of its spodumene concrete production.

In light of the above, it certainly look likely to be a busy 12 months for Piedmont Lithium and its shareholders.

More reading

• Piedmont Lithium (ASX:PLL) successfully completes US public offering
• Piedmont Lithium (ASX:PLL) shares in trading halt after proposed US public offering
• Victoria to tax electric vehicles? What this could mean for ASX lithium shares
• These are the top performing ASX lithium stocks in 2021 so far
• Why the Piedmont Lithium (ASX:PLL) share price is zooming 9% higher today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Here’s why the Piedmont Lithium (ASX:PLL) share price is crashing 17% lower appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3fcSVdC

Shares in ASX technology company Bigtincan Holdings Ltd (ASX: BTH) enjoyed a stellar run over the latter half of 2020. In fact, by late October, the Bigtincan share price had reached a record high of $1.60. But since then, the company’s shares have well and truly come off the boil, retreating by almost 44% to just 88.5 cents at the time of writing.

Currently, the Bigtincan share price is trading at its lowest level since August of last year, reversing more than 6 months worth of gains.

Company background

Bigtincan develops sales and marketing software for business clients. It services a range of different industries from healthcare and life sciences to manufacturing and financial services. Bigtincan’s software is designed to automate manual processes, improving customer and stakeholder engagement. Additionally, the software helps boost productivity, and drive better sales and marketing outcomes.

Bigtincan’s flagship Sales Enablement Automation Platform is a centralised, integrated software solution. The platform is designed to support businesses throughout their entire sales and marketing lifecycle. This starts from onboarding, training and coaching new staff, and assists in engaging with customers and providing accurate, dynamic reporting.

What drove the Bigtincan share price gains in 2020?

Despite the challenges posed by the COVID-19 pandemic, FY20 was an exciting year for the company. Bigtincan made three key strategic acquisitions during FY20. The most in its history. It also delivered some strong results in tough market conditions.

Revenues surged 56% higher in FY20 to $31 million, with a great deal of that uplift coming from subscription revenue. Consequently, subscription revenue increased by 57% to $29.5 million. Customer retention rates also increased by 2% to 89%, indicating significant brand loyalty among Bigtincan’s client base.

More recent news

Bigtincan released its first-half FY21 results to the market last month. It was another strong result, with revenues increasing by 33% versus the first half of FY20 to $18.4 million. It also delivered annualised recurring revenues that were up 50% on the prior corresponding period to $48.4 million.

The company also kept up its rate of M&A activity, making two additional acquisitions during the half. Its most significant acquisition was of sales enablement software developer Clearslide. Clearslide is an international industry leader with over 500 customers on multiple continents.

Outlook for Bigtincan

The company also reaffirmed its FY21 guidance. Annualised recurring revenue is expected to come in at the upper end of the $49 million to $53 million band. Statutory revenue is anticipated to be in the range of $41 million to $44 million. This would imply year-on-year growth of at least 32%.

However, this news did little to buoy the Bigtincan share price. Shares fell almost 9% the day of the company’s first-half results announcement, and they have only increased marginally since then. With all signs pointing to another year of solid growth, it will be interesting to watch Bigtincan shares perform over the remainder of FY21.

More reading

• 2 of the best small cap ASX shares to buy
• 3 small cap ASX shares rated as buys
• 2 excellent ASX growth shares to buy
• ASX tech correction? 10 of the worst-hit shares
• ASX All Technology Index teetering on verge of a bear market

Rhys Brock owns shares of BIGTINCAN FPO. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends BIGTINCAN FPO. The Motley Fool Australia has recommended BIGTINCAN FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Bigtincan (ASX:BTH) share price continues slide despite strong underlying growth appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3d6kKSo

The Incannex Healthcare Ltd (ASX: IHL) share price is climbing on the back of a positive update regarding its therapy, IHL-675A.

At the time of writing, the healthcare company’s shares are up 5%, trading at 21 cents.

What did Incannex announce?

The Incannex share price is on the move today as investors appear pleased with the company’s progress.

In its release, Incannex advised that it has been granted a pre-IND meeting with the United States Food and Drug Administration (FDA). The meeting follows the company’s submitted information package, which contained details of IHL-675A and its medical benefits.

IHL-675A is a novel therapy that comprises hydroxychloroquine (HCQ) and cannabidiol (CBD) for the potential treatment of Acute Respiratory Distress Syndrome (ARDS) and sepsis-associated Adult Respiratory Distress Syndrome (SAARDS).

Incannex stated that the FDA is scheduled to provide feedback on the development proposal for IHL-675A by 21 April 2021. Once received, the company will seek to finalise clinical development plans with suggestions from the FDA.

The purpose of the pre-IND meeting is to explore the fastest pathway for IHL-675A to be given its registration stamp.

ARDS is a type of respiratory failure which collects fluid into the air sacs of the lungs. This is often caused by infection or trauma and can result in death if not treated. It is estimated that 10% to 15% of patients admitted to intensive care suffering from ARDS.

SAARDS, caused by infection, is associated with lung, urinary tract, stomach, skin infections and COVID-19 viral infections.

Management commentary

Incannex CEO and managing director Joel Latham welcomed the positive outcome, saying:

The United States is the largest pharmaceutical market in the world, so being granted a Pre-IND meeting review with FDA represents an important milestone for our company and a strong foundation for the clinical development of IHL-675A.

Our preclinical studies have demonstrated that IHL-675A has the potential to be a platform drug applicable to the treatment of multiple indications. We anticipate that the work completed on the FDA information package for IHL-675A for ARDS and SAARDS will assist us with hastening submissions to FDA for the other indications being pursued.

About the Incannex share price

The Incannex share price has gained more than 500% in the past 12 months and is up almost 30% year-to-date. The company’s shares reached a multi-year high of 29.5 cents in the last month.

Incannex commands a market capitalisation of around $211 million, with roughly 1 billion shares on issue.

More reading

• Here’s why the Incannex (ASX:IHL) share price is up 10% today.
• Up 300% in 1 year, what’s driving the Incannex Healthcare (ASX:IHL) share price?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Incannex (ASX:IHL) share price is climbing 5% this morning appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3tRlXno

The Accent Group Ltd (ASX: AX1) share price is pushing higher on Thursday morning.

At the time of writing, the footwear focused retailer’s shares are up 1.5% to $2.35.

Why is the Accent share price rising?

Investors have been buying Accent shares this morning following the release of an analyst day presentation.

While the presentation didn’t include a trading update, it did come with some valuable information for investors and shareholders.

Store network growth

Accent is continuing to grow its store network and expects to add 90 stores across its numerous brands during FY 2021.

This will bring the total stores in its network up to 609. Given how many retailers have closed down over the last 12 months, this store growth appears to demonstrate the strength and resilience of its business.

New store brand

The company has been busy launching new store brands over the last couple of years. This includes Pivot, Stylerunner, and Subtype (Sneaker LAB).

Management isn’t resting on its laurels and has announced a new store brand launch this morning – 4 Workers.

The presentation explains that 4 Workers, which will open its first store in May, is designed to appeal to workers such as nurses, chefs, tradies, among others. It will stock footwear and clothing that caters to the healthcare, hospitality, construction, and corporate sectors.

Management believes there is a significant opportunity to capture share in a fast growing market segment.

Loyalty programs

Accent also spoke about the success it is having with its loyalty programs.

It now has over 3.3 million MyFit members and has recently launched the Skechers Insider program. The latter has been a huge success, with 188,000 members joining the program within two weeks of launch.

Accent share price performance

Following today’s gain, the Accent share price is now up 49% over the last six months.

One broker that thinks it can go higher is Bell Potter. Last month its analysts put a buy rating and $2.65 price target on its shares.

More reading

• Is Temple & Webster (ASX:TPW) the best e-commerce ASX share to buy right now?
• ASX retail shares beware: Aldi e-commerce is coming
• 3 under-appreciated income stocks yielding 4-9%: Motley Fool CIO Scott Phillips, on ausbiz
• 2 quality ASX dividend shares to buy today
• Got money to invest for dividends? Here are 2 ASX shares

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Accent Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Accent (ASX:AX1) share price is pushing higher today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3d0Z7Ty

The Qantas Airways Limited (ASX: QAN) share price is lifting slightly today after the competition watchdog approved its alliance with American Airlines Group Inc.

The co-operative agreement needed permission from the Australian Competition and Consumer Commission (ACCC) because it otherwise risks breaching competition laws.

The new 5-year approval allows Qantas and its budget brand Jetstar to collaborate with American Airlines on trans-Pacific routes. These include flights to and from the US, Canada and Mexico.

The Qantas share price fell 1.54% on Wednesday, while American Airlines lost 2.07% overnight.

ACCC commissioner Stephen Ridgeway said the alliance was approved because the public benefits outweighed any anti-competition potential.

“Passengers travelling on trans-Pacific routes are likely to benefit through enhanced products and services, including a greater likelihood of increased capacity and new routes, increased connectivity and improved schedule choice.

“Loyalty program benefits and improved lounge access, cost savings and efficiencies are also likely to be a result.”

The ACCC conceded that the fruits of the alliance won’t be seen until international travel picks up after the COVID-19 pandemic.

Great deal for Australians travelling to North America

The deal allows the airlines to synchronise on marketing and sales, pricing, scheduling, freight, inventory, frequent flyer schemes, airport lounges, procurement and service standards.

“The alliance is unlikely to result in any significant public detriment,” said Ridgeway.

“The ACCC considers that American Airlines would be unlikely to operate its own trans-Pacific services or materially expand its trans-Pacific capacity and frequency without its alliance with Qantas.”

The commission first approved the alliance back in 2011 for a 5-year term, then renewed it in 2016. Qantas and American approached the ACCC in October for another 5-year term.

The ACCC authorisation gives the airlines legal protection for actions that might otherwise get them in trouble for their anti-competitive nature.

Qantas last estimated that international flights might resume by the end of October, while New Zealand travel may restart in July.

At the time of writing, the Qantas share price is trading at $5.13.

More reading

• The Regional Express (ASX:REX) share price has fallen after fresh Qantas challenge
• Did Powell just blink first in the Fed’s staring contest with inflation?
• How are ASX 200 shares faring in the carbon revolution?
• Will the Qantas (ASX:QAN) share price soar 20% higher from here?
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor Tony Yoo owns shares of Qantas Airways Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Qantas (ASX:QAN) share price lifts after ACCC ruling appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3cjOwDP

The McPherson’s Ltd (ASX: MCP) share price is surging notably higher on Thursday morning.

At the time of writing, the personal care and beauty products company’s shares are up 14% to $1.39.

Why is the McPherson’s share price surging higher?

Investors have been fighting to get hold of shares this morning after McPherson’s announced the receipt of a takeover approach.

According to the release, Gallin Pty Ltd has made an unconditional on-market takeover offer of $1.34 cash per share.

While this represents a 9.8% premium to its last close price, it is a very opportunistic 60% discount to its 52-week high.

What is Gallin Pty Ltd?

A separate release explains that Gallin has been incorporated specifically for the purpose of acquiring an interest in McPherson’s.

All of the shares in Gallin are owned by Bennamon Pty Ltd, which is wholly owned by Kin Group, which is ultimately controlled by the Geminder family. Kin Group also owns a significant stake in Pact Group Holdings Ltd (ASX: PGH), among many other investments.

Gallin has been quietly building up a position in McPherson’s over the last few months and, prior to today, owned a 4.95% stake.

“McPherson’s has lost its way”

Gallin’s Director, Nick Perkins, believes McPherson’s has lost its way and needs new leadership.

He said, “McPherson’s is a business that has lost its way and is in urgent need of reinvigoration across its strategy, governance, and leadership. The company’s performance has disappointed shareholders for some time despite owning a number of quality, attractive brands across key consumer markets.”

“Now investors face a further extended period of uncertainty, including a lack of visibility on the current performance of sales of the Dr. LeWinn’s product range into China. Although highly uncertain and with no guarantee of success, McPherson’s urgently needs to undertake a full operational and strategic review with a view of turning around the business. We have the capital, capability, wherewithal and patience to do this, while shareholders have an opportunity to receive cash now at an attractive premium.”

Gallin also took aim at management’s poor M&A track record, its history of one-off adjustments, and wasted capital.

It concluded: “McPherson’s also has a relatively poor M&A track record and a history of recognising “one-off” adjustments. Notably, between FY16 and 1H FY21 there has been c. $56.7 million4 in one-off impairments, inventory write-downs and restructuring costs. Moreover, the latest downgrade to the outlook on 1 December 2020 has further eroded market trust having come approximately 1 month after McPherson’s raised fresh capital from shareholders.”

More reading

• Brickworks (ASX:BKW) share price higher following half year results
• Starpharma (ASX:SPL) share price pushes higher on COVID-19 nasal spray update
• The ASX sector set to outperform this morning thanks to Suez
• Amazon reportedly demands that delivery drivers submit to invasive biometric surveillance or be fired
• Here’s an ASX tech share flying under the radar: fundie

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the McPherson’s (ASX:MCP) share price is zooming 14% higher today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2NPB3KB

In morning trade the Brickworks Limited (ASX: BKW) share price is rising following the release of its half year results.

At the time of writing, the building products company’s shares are up 2.5% to $19.41.

How did Brickworks perform in the first half?

For the six months ended 31 January, Brickworks reported a 4% decline in revenue to $432 million. This comprises Australian revenue of $330 million and North American revenue of $102 million.

It was a similar story for the company’s earnings before interest and tax (EBIT). Half year EBIT was down 6% over the prior corresponding period to $127 million.

This was driven partly by a 33% decrease in North American EBIT to $4 million following significant disruption by the COVID-19 pandemic. It partially offset a 60% lift in Australian EBIT to $16 million, which was underpinned by cost reductions.

Once again, the company’s Property Trust joint venture with Goodman Group (ASX: GMG) was its saving grace. It helped its Property business generate EBIT of $92 million for the half. Management notes that the business benefited from very favourable revaluations and profit on the sale of land.

On the bottom line, Brickworks posted an underlying net profit after tax of $90 million, which was down 10% compared to last year. However, on a statutory basis, which includes significant items, Brickworks’ net profit increased 22% to $71 million.

Positively, despite the decline in underlying profit, the Brickworks board has increased its interim dividend by 5% to 21 cents per share. This maintains its 45-year record of increasing dividends.

Outlook

Brickworks Managing Director, Mr. Lindsay Partridge, appears cautiously optimistic on the future. This is thanks to its conservative gearing, its diversified portfolio of attractive assets, and improving demand.

He said: “Development activity within the Property Trust is continuing at an unprecedented scale. This includes the construction of new facilities to meet lease pre-commitments across four of our Estates in Sydney and Brisbane. The completion of these facilities within the next two years will result in gross rent within the Trust increasing by over 40%, with significant further land remaining for development.”

Mr Partridge expects its Australian operations to perform strongly in the short term.

“Within Building Products Australia, the short-term outlook is positive, with demand gathering momentum in recent months. As demand grows, we anticipate sales volume will be limited by the availability of tradespeople such as brick layers and roof tilers, and this is likely to extend the existing pipeline of work, resulting in an elevated period of activity for at least a year. However, looking beyond the current stimulus induced surge in activity, significant uncertainty remains,” he explained.

Positively, the Managing Director notes that demand is recovering in the North American market.

“In North America, we have seen a strong recovery in demand during March, with improved weather and increased optimism of a stimulus led recovery. Daily order intake is now back to pre-pandemic levels, and as conditions continue to normalise, we are confident that our North American operations will deliver improved earnings and growth for many years to come.” “WHSP is expected to deliver a stable and growing stream of earnings and dividends over the long term,” Mr Partridge concluded.

More reading

• 5 things to watch on the ASX 200 on Thursday
• 2 leading ASX 200 dividend shares to buy for income
• 3 under-appreciated income stocks yielding 4-9%: Motley Fool CIO Scott Phillips, on ausbiz
• This ASX company has increased or maintained dividends for 44 years
• 3 reasons why Brickworks is a great ASX dividend share

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Brickworks. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Brickworks (ASX:BKW) share price higher following half year results appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3lZBr69

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Thursday morning.

At the time of writing, the dendrimer products developer’s shares are up 3.5% to $2.10.

Why is the Starpharma share price pushing higher?

Investors have been buying Starpharma’s shares this morning following the release of a positive announcement.

According to the release, the company has signed a sales and distribution agreement for its Viraleze antiviral nasal spray with Lloyds Pharmacy and the McKesson Group in the United Kingdom.

Lloyds Pharmacy and the McKesson Group is one of the largest pharmacy groups in the UK and is also a major wholesaler. It currently operates approximately 1,400 pharmacies across the country and supplies to over 14,000 independent UK pharmacies.

The release explains that Viraleze will be available online next week and is expected to be instore in April.

Starpharma’s sales and distribution agreement with the pharmacy group incorporates a reciprocal exclusivity arrangement for Viraleze. This includes significant investment in marketing by Lloyds, both online and instore.

What is Viraleze?

Viraleze is an antiviral nasal spray that was developed by Starpharma based on an already marketed active.

It contains astodrimer sodium (SPL7013), which is virucidal and irreversibly inactivates >99.9% of coronavirus/SARS-CoV-2 within one minute. Importantly, it has also demonstrated potent antiviral activity against multiple strains of SARS-CoV-2.

Starpharma’s CEO, Dr Jackie Fairley, was very pleased with the agreement.

She said: “We are excited that VIRALEZE will be available from next week in the second largest pharmacy chain in the UK.”

“The LloydsPharmacy/McKesson team shares Starpharma’s enthusiasm and commitment to bring VIRALEZE antiviral nasal spray to UK consumers as they emerge from their latest lockdown. LloydsPharmacy represents an ideal partner for this product.”

Lloyds Pharmacy’s Head of e-Commerce and Category Management, Mr John Acland, added: “We are excited to have secured exclusive rights to VIRALEZE for the UK. It is a highly innovative product with compelling customer benefits and is well supported by an impressive body of quality science and research.”

“We hope VIRALEZE will bring LloydsPharmacy customers added peace of mind and protection as we enter the next chapter of the pandemic and re-emerge back into work, school and social settings.”

More reading

• Why the Starpharma (ASX:SPL) share price is charging higher today
• Which ASX healthcare shares saw the biggest gains in February?

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Starpharma (ASX:SPL) share price pushes higher on COVID-19 nasal spray update appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/31fZxjk

The market is expected to dip on weak leads from Wall Street, but not these ASX shares that will benefit from the accident along the Suez Canal.

The Brent oil price surged 5.7% to US$64.23 a barrel while the WTI benchmark rallied 5.9% to US$61.18 a barrel.

This will likely boost ASX energy shares like the Woodside Petroleum Limited (ASX: WPL) share price, Oil Search Ltd (ASX: OSH) share price and Santos Ltd (ASX: STO) share price – just to name a few.

In contrast, the S&P/ASX 200 Index (Index:^AXJO) is expected to dip 0.2% this morning.

ASX energy shares get boost from Suez blockage

While ASX shares exposed to the oil price are likely to outperform, there will be questions about how long the rally can last.

Up to 10 crude tankers carrying around 13 million barrels of oil could be stuck in the bottleneck long the Suez Canal, reported Oilprice.com.

The key shipping channel linking Europe and Asia has been blocked after a tanker ran aground along the narrow man-made canal that opened in 1869.

Stubbornly stuck

Authorities are trying to free the vessel but with little success. It could take another day or two to free the trapped container ship.

In the meantime, around 50 vessels per day are waiting to cross the canal. Sailing around the Suez will add an extra 15 days.

Around 9 % of total seaborne traded petroleum and 12% of global trade flows through this channel, according to the U.S. Energy Information Administration.

Oil market interrupted in a good way for once

The top three exporters of crude oil and oil products via the Suez Canal so far in 2021 were Russia with 546,000 barrels per day (bpd), Saudi Arabia with 410,000 bpd, and Iraq with 400,000 bpd, reported Oilprice.com which sourced data from oil analytics firm Vortexa.

China is among the top three importers of crude and oil products that are shipped through the Suez Canal.

The cargo ship at the centre of the accident, Ever Given, is a 400-meter giant and is one of the largest vessels that sails through the Suez Canal. Ever Given is wedged sideways along the embankment on Egypt’s side, blocking the narrowest part of the canal.

Foolish takeaway

It’s not a question of “if” but “when” Ever Given will be re-floated. When that happens, the oil price could surrender recent gains.

At least for the moment, the turnaround in oil will provide some relief to the ASX energy sector. These ASX shares have been hit hard by a large drop in crude due to worries of waning demand and excess supply.

Those fears could soon remanifest as they linger for longer than Ever Given.

More reading

• 5 things to watch on the ASX 200 on Thursday
• ASX 200 rises, Airtasker soars again, Westpac considers NZ
• How is Australia’s jobs rebound affecting ASX shares?
• How are ASX 200 shares faring in the carbon revolution?
• Why Lynas, Oil Search, Pushpay, & Webjet shares are tumbling lower

Motley Fool contributor Brendon Lau owns shares of Santos Limited. Connect with me on Twitter @brenlau.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The ASX sector set to outperform this morning thanks to Suez appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2NNuwjw

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

A month after Amazon.com Inc (NASDAQ: AMZN) began outfitting its vans with new surveillance cameras equipped with artificial intelligence (AI) to keep a watchful eye on its drivers, the company is reportedly demanding that its drivers either agree to be monitored biometrically while in the vans or get fired.

Motherboard, a tech news website, reports that 75,000 US delivery drivers, as a condition of employment, are being given a consent form to sign acknowledging they agree to facial recognition and the collection of biometric data while driving company-branded vans. Amazon says the cameras are to improve driver safety.

The consent form says that to deliver packages, drivers must agree to have the vehicle tracked for location, movement, speed, acceleration, braking, turns, following distance, and more.

Earlier this year, Amazon posted a video to Vimeo to alert its delivery contractors it was installing Netradyne Driver-i cameras in its branded delivery vans, giving it a 270-degree view to monitor drivers and detect potentially risky behaviour. Incidents that trigger the cameras, such as running a stop sign or taking a corner too hard, are uploaded to Amazon’s cloud for review.

Motherboard reports the onboard AI can detect if a driver yawns, appears distracted, or isn’t wearing a seatbelt. Because of the intrusive nature of the surveillance, drivers are reportedly quitting rather than be constantly monitored. Congress has also recently questioned Amazon about its concerns over driver privacy.

Amazon Logistics delivered around 5.1 billion packages in 2020, which was just slightly fewer than the 5.3 billion that United Parcel Service Inc (NYSE: UPS) delivered, and half the total volume of all packages delivered for Amazon last year.

Most Amazon drivers don’t actually work for the company. Instead, they are employed by third-party contractors that Amazon encouraged to start their own delivery business through its delivery service partner (DSP) program.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• How to counter the ASX 200’s Achilles heel
• Why it’s a great time for ASX investors to buy US shares
• When dividends can be a bad thing for an ASX share
• Amazon expands road testing of Rivian electric delivery vans
• 2 ETFs to buy today for future-proof ASX diversification

Rich Duprey has no position in any of the stocks mentioned. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Amazon and recommends the following options: long January 2022 $1920 calls on Amazon and short January 2022 $1940 calls on Amazon. The Motley Fool Australia has recommended Amazon. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Amazon reportedly demands that delivery drivers submit to invasive biometric surveillance or be fired appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/31hcTMk